MA32376B1 - VACCIN CONTRE LA LEISHMANIOSE UTILISANT UN IMMUNOGèNE SALIVAIRE DE PHLÉBOTOME - Google Patents

VACCIN CONTRE LA LEISHMANIOSE UTILISANT UN IMMUNOGèNE SALIVAIRE DE PHLÉBOTOME

Info

Publication number
MA32376B1
MA32376B1 MA33392A MA33392A MA32376B1 MA 32376 B1 MA32376 B1 MA 32376B1 MA 33392 A MA33392 A MA 33392A MA 33392 A MA33392 A MA 33392A MA 32376 B1 MA32376 B1 MA 32376B1
Authority
MA
Morocco
Prior art keywords
leishmaniasis
immunosuppressant
fever
vaccine
longipalpis
Prior art date
Application number
MA33392A
Other languages
Arabic (ar)
English (en)
Inventor
Laurent Bernard Fischer
Jesus G Valenzuela
Original Assignee
Merial Ltd
Gov Of The Usa As Represented By The Secretary Of The Dept Of Health & Humain Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd, Gov Of The Usa As Represented By The Secretary Of The Dept Of Health & Humain Services filed Critical Merial Ltd
Publication of MA32376B1 publication Critical patent/MA32376B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Insects & Arthropods (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des vecteurs qui contiennent et expriment in vivo ou in vitro des antigènes salivaires du phlébotome lu. Longipalpis capables de susciter une réponse immunitaire contre la leishmaniose chez l'animal ou l'être humain, des compositions vaccinales comprenant lesdits vecteurs et/ou des polypeptides salivaires de lu. Longipalpis, des procédés de vaccination contre la leishmaniose et des nécessaires à utiliser avec lesdits procédés et compositions.
MA33392A 2008-05-08 2010-12-03 VACCIN CONTRE LA LEISHMANIOSE UTILISANT UN IMMUNOGèNE SALIVAIRE DE PHLÉBOTOME MA32376B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5163508P 2008-05-08 2008-05-08
US10134508P 2008-09-30 2008-09-30
PCT/US2009/042980 WO2009137577A2 (fr) 2008-05-08 2009-05-06 Vaccin contre la leishmaniose utilisant un immunogène salivaire de phlébotome

Publications (1)

Publication Number Publication Date
MA32376B1 true MA32376B1 (fr) 2011-06-01

Family

ID=41110966

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33392A MA32376B1 (fr) 2008-05-08 2010-12-03 VACCIN CONTRE LA LEISHMANIOSE UTILISANT UN IMMUNOGèNE SALIVAIRE DE PHLÉBOTOME

Country Status (10)

Country Link
US (2) US8603808B2 (fr)
EP (2) EP2283035B1 (fr)
CN (2) CN102066411A (fr)
AR (1) AR071696A1 (fr)
BR (1) BRPI0915605B8 (fr)
ES (1) ES2760004T3 (fr)
IL (1) IL209107A (fr)
MA (1) MA32376B1 (fr)
MX (2) MX348137B (fr)
WO (1) WO2009137577A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2283035B1 (fr) * 2008-05-08 2015-07-29 Merial Limited Vaccin contre la leishmaniose utilisant un immunogène salivaire de phlébotome
AU2013308623B2 (en) 2012-08-30 2017-03-02 Merial, Inc. Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins
EP2935581A4 (fr) * 2012-12-21 2016-07-27 Merck Sharp & Dohme Vecteurs d'expression utilisables en vue de la production de protéines recombinées dans des cellules de mammifère
US10010499B2 (en) 2014-11-03 2018-07-03 Merial Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
AR111842A1 (es) 2017-06-02 2019-08-21 Amgen Inc Antagonistas de péptido pac1
CN113337542A (zh) * 2021-06-10 2021-09-03 山西大学 高效表达利什曼原虫pepck的人复制缺陷型重组腺病毒载体

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
FR2603899B1 (fr) 1986-09-12 1990-07-13 Genentech Inc Procede perfectionne pour l'expression de recombinants
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
CA2003300A1 (fr) 1988-11-21 1990-05-21 Franklin Volvovitz Cutireaction et trousse pour le depistage du sida
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5529780A (en) 1994-03-30 1996-06-25 Virogenetics Corporation Nucleotide and amino acid sequences of canine herpesvirus gB and gC
CA2214029A1 (fr) 1995-04-25 1996-10-31 Magda Marquet Formulations en ampoule unidose de complexes adn/lipides
EP0803573A1 (fr) 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Construction pour l'expression polycistronique contenant des cytokines pour des vaccins multivalents
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2750865B1 (fr) 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
EP0979101B1 (fr) 1996-07-03 2010-10-27 Merial, Inc. ADENOVIRUS CANIN 2 RECOMBINANT (ACR2) CONTENANT DE l'ADN EXOGENE
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
TWI224107B (en) 1998-10-22 2004-11-21 Pfizer Prod Inc Novel proteins from actinobacillus pleuropneumoniae
US6017537A (en) 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
FR2796397B1 (fr) 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
ES2248126T3 (es) 1999-09-25 2006-03-16 University Of Iowa Research Foundation Acidos nucleicos inmunoestimuladores.
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
EP1203819A3 (fr) 2000-10-06 2002-08-07 Transgene S.A. Vecteurs anti-inflammatoires
BR0210539A (pt) * 2001-06-19 2005-04-26 Us Gov Health & Human Serv Processos de seleção e uso de vacinas de vetor antiartrópode
FR2829498B1 (fr) 2001-09-11 2003-11-28 Merial Sas Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
US7078507B2 (en) 2001-11-09 2006-07-18 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Synthetic genes for malarial proteins and methods of use
WO2004024027A2 (fr) 2002-06-07 2004-03-25 University Of Florida Limes endodontiques fabriquees au moyen de verres metalliques en vrac
MXPA05004714A (es) * 2002-10-29 2006-03-17 Us Gov Health & Human Serv Polipeptidos de lutzomyia longipalpis y metodos de uso.
DE502004005784D1 (de) * 2003-10-24 2008-02-07 Mologen Ag Mittel zur behandlung von infektionen mit leishmanien
CN1997389B (zh) 2004-06-04 2010-06-16 梅瑞尔有限公司 FeLV疫苗的无针施用
US7512883B2 (en) * 2004-06-30 2009-03-31 Microsoft Corporation Portable solution for automatic camera management
CA2540736A1 (fr) * 2005-04-08 2006-10-08 Institut Pasteur Polypeptides de leishmania major et polynucleotides les encodant, applications vaccinales, therapeutiques et diagnostiques de ceux-ci
CA2670097C (fr) * 2006-11-21 2015-10-06 Merial Limited Vaccin contre la leishmania canine
US20100278752A1 (en) * 2007-08-02 2010-11-04 Rhode Island Board Of Governors For Higher Education Methods for Detection and Prevention of Tick Infestation and Pathogen Transmission
EP2283035B1 (fr) * 2008-05-08 2015-07-29 Merial Limited Vaccin contre la leishmaniose utilisant un immunogène salivaire de phlébotome
WO2009143006A1 (fr) * 2008-05-21 2009-11-26 Infectious Disease Research Institute Vaccins polyprotéiques recombinants destinés au traitement et au diagnostic de la leishmaniose
US8410258B2 (en) * 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
WO2010078466A2 (fr) * 2008-12-31 2010-07-08 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Protéines salivaires de phlébotome avec une activité anticomplément et leurs procédés d'utilisation
WO2010078469A2 (fr) * 2008-12-31 2010-07-08 The Usa As Represented By The Secretary, Department Of Health And Human Services Protéines salivaires de phlébotome en tant que nouveaux inhibiteurs du facteur xa et procédés d'utilisation
CN107412756A (zh) * 2010-10-01 2017-12-01 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
WO2012068077A1 (fr) * 2010-11-18 2012-05-24 Merial Limited Modèle de provocation de la leishmaniose canine par piqûres de phlébotomes
WO2013011184A2 (fr) * 2011-07-21 2013-01-24 Consejo Superior De Investigaciones Científicas (Csic) Molécule chimère utilisée en immunothérapie face à la leishmaniose qui comprend un fragment de la protéine pfr1de leishmania infantum avec des épitopes spécifiques immunodominants
WO2013142371A1 (fr) * 2012-03-20 2013-09-26 Merial Limited Vaccin contre l'herpèsvirus équin 1 recombinant contenant une glycoprotéine c mutée et utilisations associées

Also Published As

Publication number Publication date
BRPI0915605B8 (pt) 2021-09-08
EP2899203A2 (fr) 2015-07-29
CN102066411A (zh) 2011-05-18
EP2283035A2 (fr) 2011-02-16
US9228002B2 (en) 2016-01-05
EP2899203B1 (fr) 2019-07-10
US20090324649A1 (en) 2009-12-31
BRPI0915605A2 (pt) 2016-02-02
ES2760004T3 (es) 2020-05-12
WO2009137577A3 (fr) 2010-03-25
HK1150616A1 (zh) 2012-01-06
MX348137B (es) 2017-05-29
EP2283035B1 (fr) 2015-07-29
IL209107A0 (en) 2011-01-31
WO2009137577A2 (fr) 2009-11-12
EP2899203A3 (fr) 2015-08-05
CN103768588A (zh) 2014-05-07
IL209107A (en) 2017-08-31
AR071696A1 (es) 2010-07-07
MX2010012069A (es) 2010-12-14
US20140294875A1 (en) 2014-10-02
BRPI0915605B1 (pt) 2021-08-24
US8603808B2 (en) 2013-12-10

Similar Documents

Publication Publication Date Title
EA201070329A1 (ru) Векторы и конструкции для доставки гриппозного антигена
WO2005099752A3 (fr) Vecteurs et constructions d'administration d'antigenes
EP2517557A3 (fr) Modèles animaux et molécules thérapeutiques
MA32376B1 (fr) VACCIN CONTRE LA LEISHMANIOSE UTILISANT UN IMMUNOGèNE SALIVAIRE DE PHLÉBOTOME
WO2007100908A3 (fr) Vecteurs anédoviraux chimériques
GT200800132A (es) Anticuerpos anti-il-23 humanos, composiciones, metodos y usos
CU20120095A7 (es) Antagonistas de pcsk9
MX2009006594A (es) Formulaciones de ph regulado y estables que contienen polipeptidos.
WO2009133378A3 (fr) Produits et procédés permettant de stimuler une réponse immunitaire
EA200701362A1 (ru) Агонисты glp-1, композиции, способы и применения
TR201000668T1 (tr) Neoplasti̇k veya enfeksi̇yoz bozukluklara yöneli̇k i̇mmunoprofi̇laksi̇ veya i̇mmünoterapi̇ i̇çi̇n poli̇pepti̇d-nüklei̇k asi̇t konjugati
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
SV2006002513A (es) Anticuerpos anti-il-6, composiciones, metodos y usos ref. docket cen5094svnp
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
EA200702532A1 (ru) Антитела против мср-1, композиции, способы и применения
WO2012135701A3 (fr) Compositions et procédés pour la détection d'anaplasma platys
WO2006090389A3 (fr) Nouveaux marqueurs diagnostiques, en particulier pour l'imagerie in vivo, et dosage et procedes d'utilisation associes
EP2473051A4 (fr) Nouvelles compositions et procédés de préparation de 5-amino ou amino substitué 1,2,3-triazoles et de formulations d'orotate de triazole
CL2011002994A1 (es) Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal.
WO2008103819A3 (fr) Pseudo-particules virales (vlp) chimériques de la maladie de newcastle
MA31014B1 (fr) Vaccin contre la leishmania canine.
MA32770B1 (fr) Anticorps anti-peptides igf-1/e humain modifie
IN2014CN00547A (fr)
MX361804B (es) Vacunas genéticas contra el virus hendra y el virus nipah.
WO2006117538A3 (fr) Dosages et leur utilisation